Evaluación del uso del misoprostol en la inducción de parto en gestantes atendidas en el servicio del gineco/obstetricia del Hospital Alfredo Noboa Montenegro, Guaranda enero - julio del 2024.
| dc.contributor.advisor | Díaz Ruiz, Genesis Natali | |
| dc.contributor.author | Chávez Llanos, Anshela Brigitte | |
| dc.contributor.author | Núñez Guasgua, Karen Lizbeth | |
| dc.date.accessioned | 2024-10-11T03:40:03Z | |
| dc.date.available | 2024-10-11T03:40:03Z | |
| dc.date.issued | 2024 | |
| dc.identifier.uri | http://dspace.utb.edu.ec/handle/49000/17527 | |
| dc.description | The main objective of the study was to determine the safety and effectiveness of misoprostol in labor induction, comparing different doses and administration methods. A quantitative and descriptive approach was used to analyze a sample of 59 pregnant women who were between 37 and 40.5 weeks of gestation. Data were collected from medical records and analyzed statistically. The results indicated that the 25-mcg sublingual dose was the most effective, while 74% of inductions with misoprostol culminated in successful vaginal deliveries, and 26% required cesarean section. 15% of cases presented side effects, with tachysystole being the most common. To reduce risks, the study proposed standardizing the use of misoprostol with specific doses and rigorous monitoring. Misoprostol proved to be a safe and effective medication for inducing labor, with considerable success in vaginal deliveries, confirming its usefulness in obstetric practice. The important keywords were: misoprostol, induction of labor, safety, dosage and adverse effects. The findings suggested that the Alfredo Noboa Montenegro Hospital establish a standard protocol for the use of misoprostol in labor induction. Given its high success rate in inducing vaginal births and its acceptable safety profile, the 25 mcg sublingual dose should be included as an initial standard in this protocol. Finally, it was recommended to conduct more studies to evaluate the application of these recommendations in various contexts and adapt the protocol to the specific needs of the population served. | es_ES |
| dc.description | The main objective of the study was to determine the safety and effectiveness of misoprostol in labor induction, comparing different doses and administration methods. A quantitative and descriptive approach was used to analyze a sample of 59 pregnant women who were between 37 and 40.5 weeks of gestation. Data were collected from medical records and analyzed statistically. The results indicated that the 25-mcg sublingual dose was the most effective, while 74% of inductions with misoprostol culminated in successful vaginal deliveries, and 26% required cesarean section. 15% of cases presented side effects, with tachysystole being the most common. To reduce risks, the study proposed standardizing the use of misoprostol with specific doses and rigorous monitoring. Misoprostol proved to be a safe and effective medication for inducing labor, with considerable success in vaginal deliveries, confirming its usefulness in obstetric practice. The important keywords were: misoprostol, induction of labor, safety, dosage and adverse effects. The findings suggested that the Alfredo Noboa Montenegro Hospital establish a standard protocol for the use of misoprostol in labor induction. Given its high success rate in inducing vaginal births and its acceptable safety profile, the 25 mcg sublingual dose should be included as an initial standard in this protocol. Finally, it was recommended to conduct more studies to evaluate the application of these recommendations in various contexts and adapt the protocol to the specific needs of the population served. | es_ES |
| dc.description.abstract | El objetivo principal del estudio fue determinar la seguridad y eficacia del misoprostol en la inducción del parto, comparando diferentes dosis y métodos de administración. Se empleó un enfoque cuantitativo y descriptivo para analizar una muestra de 59 gestantes que se encontraban entre las 37 y 40.5 semanas de gestación. Los datos fueron recopilados de historias clínicas y analizados estadísticamente. Los resultados indicaron que la dosis de 25 mcg vía sublingual fue la más efectiva, mientras que el 74% de las inducciones con misoprostol culminaron en partos vaginales exitosos, y el 26% requirió cesárea. El 15% de los casos presentaron efectos secundarios, siendo la taquisistolia el más común. Para reducir los riesgos, el estudio propuso estandarizar el uso de misoprostol con dosis específicas y un monitoreo riguroso. El misoprostol demostró ser un medicamento seguro y efectivo para inducir el parto, con un éxito considerable en partos vaginales, lo que confirmó su utilidad en la práctica obstétrica. Las palabras clave importantes fueron: misoprostol, inducción del parto, seguridad, dosis y efectos adversos. Los hallazgos sugirieron que el Hospital Alfredo Noboa Montenegro estableciera un protocolo estándar para el uso de misoprostol en la inducción del parto. Dado su alto índice de éxito en la inducción de partos vaginales y su perfil de seguridad aceptable, la dosis de 25 mcg por vía sublingual debía incluirse como estándar inicial en este protocolo. Finalmente, se recomendó realizar más estudios para evaluar la aplicación de estas recomendaciones en diversos contextos y adaptar el protocolo a las necesidades específicas de la población atendida. | es_ES |
| dc.format.extent | 122 p. | es_ES |
| dc.language.iso | es | es_ES |
| dc.publisher | Babahoyo: UTB-FCS, 2024 | es_ES |
| dc.rights | Atribución-NoComercial-SinDerivadas 3.0 Ecuador | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/ec/ | * |
| dc.subject | Misoprostol | es_ES |
| dc.subject | Inducción del parto | es_ES |
| dc.subject | Seguridad | es_ES |
| dc.subject | Dosis | es_ES |
| dc.subject | Efectos adversos | es_ES |
| dc.subject.other | Obstetricia | es_ES |
| dc.title | Evaluación del uso del misoprostol en la inducción de parto en gestantes atendidas en el servicio del gineco/obstetricia del Hospital Alfredo Noboa Montenegro, Guaranda enero - julio del 2024. | es_ES |
| dc.type | bachelorThesis | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Ecuador